Onconova Therapeutics, a clinical-stage biopharmaceutical company, has its sights set on developing innovative products for cancer treatment in the United States. Currently boasting two clinical-stage programs, including the Phase I narazaciclib study for solid tumors and hematological malignancies as a single agent or with other anti-cancer therapies, as well as the Phase I/IIa study of oral rigosertib alone and in combination with PD-1 inhibitor for progressive K-Ras mutated non-small cell lung cancer, Onconova Therapeutics is keen on making substantial strides in the fight against cancer. The company is also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced and metastatic squamous cell carcinoma complemented with recessive dystrophic epidermolysis bullosa. To further its efforts, Onconova Therapeutics has a license and collaboration agreement with HanX Biopharmaceuticals for narazaciclib registration, development, and commercialization in China. Onconova Therapeutics was established in 1998 and has its base in Newtown, Pennslyvania.
Onconova Therapeutics's ticker is ONTX
The company's shares trade on the NASDAQ stock exchange
They are based in Newtown, Pennsylvania
There are 11-50 employees working at Onconova Therapeutics
It is onconova.com
Onconova Therapeutics is in the Healthcare sector
Onconova Therapeutics is in the Biotechnology industry
The following five companies are Onconova Therapeutics's industry peers: